YOUR TREATMENT JOURNEY

Preparing for Treatment

Before the first dose, Dr. Peters reviews the testing and clinical information already available and determines what still needs to be completed or updated.
The Cognitive Care Program helps coordinate the remaining requirements, which may include brain MRI, laboratory testing, biomarker confirmation, APOE genetic testing, or other studies needed to confirm treatment readiness and safety.
The program also tracks results and helps make sure the necessary information is available for Dr. Peters to review before treatment begins.
The goal is simple: all required clinical and safety information should be in place before the first infusion.

​​​​​

What Happens During Treatment?

Once treatment begins, care occurs across several settings. The infusion provider administers Leqembi or Kisunla, imaging centers perform required MRI scans, and other laboratories or facilities may complete additional testing. Dr. Peters and the Cognitive Care Program help bring those pieces together and provide the ongoing neurologic oversight needed throughout treatment.

Your Infusions

Leqembi or Kisunla is administered according to its prescribed schedule through the infusion provider. The infusion team is responsible for administering the medication and addressing immediate problems that occur during an infusion.​

​

Required MRI Safety Monitoring

MRI scans are required at specific points during treatment to look for brain swelling or bleeding associated with anti-amyloid therapy. These scans are an essential part of treatment safety, not optional follow-up.
The Cognitive Care Program helps track required imaging and results so that Dr. Peters can review important findings and determine whether treatment can continue as planned. A missed or delayed safety MRI may require an infusion to be postponed until the necessary imaging has been completed and reviewed. 

​

Follow-Up With Dr. Peters

Dr. Peters continues to provide neurologic care throughout treatment. Follow-up includes a visit approximately one week after the first infusion and then approximately every 90 days, with additional visits or communication when needed. 
These visits allow Dr. Peters to assess symptoms, review treatment tolerance and safety results, follow cognitive and functional changes, and address other Alzheimer’s-related concerns.

​

Testing and Results Between Visits

Treatment may require laboratory tests, MRI scans, PET imaging, or other studies at different times. These tests may occur at facilities outside Dr. Peters’ office.
The Cognitive Care Program helps coordinate these requirements, tracks results, and helps make sure that important information reaches Dr. Peters when clinical decisions are needed.

​

Treatment Decisions Along the Way

Anti-amyloid treatment is not simply placed on autopilot once it begins. Dr. Peters reviews the patient’s clinical status and relevant safety information throughout therapy.
Depending on symptoms, MRI findings, other test results, or changes in the patient’s health, he may recommend that treatment continue, pause, resume, change, or stop.
 

​

​

Your Role During Treatment

Anti-amyloid treatment requires regular infusions, MRI scans, follow-up visits, and communication with the care team. Your participation helps keep treatment safe and on schedule.
During treatment, you are expected to:

• Attend scheduled infusions, MRI scans, laboratory testing, and follow-up visits. 

• Complete required safety monitoring before the next treatment when instructed. 

• Report new or worsening symptoms promptly. 

• Tell the care team about important changes in your health or medications, especially if considering starting a blood thinner. 

• Keep your contact information and care-partner information current. 

• Contact the Cognitive Care Team when questions or concerns arise. 

• Seek emergency care for urgent or severe symptoms rather than waiting for a response from the program. 

If required safety testing is missed or delayed, treatment may need to be postponed until the necessary information is available for Dr. Peters to review.

​

Your Care Partner’s Role

A care partner is an important part of the Cognitive Care Program. This may be a spouse, family member, or another trusted person you choose to involve in your care.
Your care partner can help keep track of appointments, infusions, MRI scans, and other testing; notice and report changes in memory, function, or health; and help you understand information and decisions throughout treatment.
The care partner also provides an important perspective during follow-up visits. Changes in memory or daily function are sometimes easier for someone close to the patient to recognize, and that information can help Dr. Peters assess how treatment and the disease are progressing.
The amount of help you need may change over time. The goal is for you and your care partner to have the information and support needed to navigate treatment together.

​

When Should You Contact the Cognitive Care Program?

Contact the Cognitive Care Program whenever something changes that could affect your treatment or safety, or when you are unsure what to do next.
This includes new or worsening neurologic symptoms, significant changes in your health, a hospitalization or emergency department visit, changes in medications, missed or delayed MRI scans or other required testing, or questions about your treatment plan.
For routine questions, scheduling concerns, or nonurgent symptoms, use the program’s dedicated contact information. Problems that occur during an infusion should be addressed first by the infusion provider.

The Cognitive Care Program is not an emergency service. If you develop severe or sudden symptoms that may require urgent medical attention, seek emergency care rather than waiting for a response from the program.

​

​

Schedule an Appointment